Latest studies
- Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)South Korea - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerSouth Korea - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
Hodgkin LymphomaSouth Korea - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
Ovarian CancerSouth Korea - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionSouth Korea - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerSouth Korea - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaSouth Korea - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskSouth Korea - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusSouth Korea - RecruitingPHASE2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
This study is testing a new medicine, ADX-038, for adults with certain kidney diseases caused by a problem with the body's immune system, called the complement system. We want to see if it's safe and helps people with conditions like IgA nephropathy (IgAN) or C3 glomerulopathy (C3G).
IgANC3GComplement-mediated Kidney DiseaseIgA Nephropathy (IgAN)South Korea - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseSouth Korea - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerSouth Korea - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaSouth Korea - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateSouth Korea - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisSouth Korea - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)South Korea - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsSouth Korea - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinSouth Korea - Enrolling by invitationPHASE2, PHASE3
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
This study is for cancer patients already taking the drug futibatinib in another study. It lets them continue treatment if it's helping and safe, ensuring ongoing care without interruption.
Advanced/Metastatic CancerSouth Korea - RecruitingPHASE1, PHASE2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called linvoseltamab for adults with multiple myeloma that hasn't responded to other treatments. We want to find the safest and most effective dose, understand its side effects, and see if it can help treat the cancer.
Multiple MyelomaSouth Korea - Active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
Generalized Myasthenia GravisSouth Korea - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerSouth Korea - RecruitingPHASE3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
This study looks at a new medicine called ravulizumab for adults receiving a kidney transplant from a deceased donor. It aims to see if this medicine can help their new kidney start working well faster, reducing the need for dialysis after the operation.
Delayed Graft FunctionDGFKidney TransplantSouth Korea - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)South Korea - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationSouth Korea - Active not recruitingPHASE3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is testing a new medicine, Tinengotinib, for people with a type of bile duct cancer called cholangiocarcinoma. It's for those whose cancer has specific genetic changes (FGFR-altered) and hasn't responded to previous treatments, including an FGFR inhibitor drug. Researchers want to see if Tinengotinib is safe and works better than other treatments.
CholangiocarcinomaSouth Korea - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsSouth Korea - RecruitingPHASE3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
This study looks at a new medicine for muscle-weakening conditions called dermatomyositis (DM) and polymyositis (PM). It aims to see how well the medicine, called dazukibart, works to help people with these conditions and if it’s safe.
MyositisSouth Korea - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaSouth Korea - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSouth Korea - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerSouth Korea - RecruitingPHASE2
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This study is testing a new medicine called axatilimab for chronic graft-versus-host disease (cGVHD) in people who haven't responded well to other treatments. It will see how well axatilimab works at three different dose levels and if it’s safe to use.
Chronic Graft-versus-host-diseaseSouth Korea - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
Metastatic Castration-resistant Prostate CancerSouth Korea - RecruitingPHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.
Non Small Cell Lung CancerSouth Korea - Active not recruitingPHASE3
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
This study investigates a new drug, elafibranor, for adults with Primary Biliary Cholangitis (PBC). It aims to see if elafibranor can improve liver health in people whose current treatment isn't working well or who can't tolerate it. It compares elafibranor to a dummy treatment.
Primary Biliary CholangitisSouth Korea - Active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
Chronic Kidney DiseaseCKDCardiac DiseaseCardiopulmonary BypassSouth Korea - RecruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
Neovascular Age-related Macular DegenerationSouth Korea - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesSouth Korea - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticSouth Korea - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
Multiple MyelomaSouth Korea - Active not recruitingPHASE2, PHASE3
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
This study tests a special cream (AC-203) for a skin condition called Epidermolysis Bullosa Simplex (EBS). It looks at how well the cream works to reduce blistering and how safe it is for people with widespread EBS, including children.
Generalized Epidermolysis Bullosa SimplexSouth Korea - Active not recruitingPHASE3
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is looking into a new drug, garetosmab, for adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to find out if it's safe, how well it works, and if it helps with FOP symptoms. It's a Phase 3 trial, meaning it's in the later stages of testing.
Fibrodysplasia Ossificans ProgressivaSouth Korea - Active not recruitingPHASE2
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
This study is testing a new medicine, ENV-101, for people with lung scarring conditions like Idiopathic Pulmonary Fibrosis (IPF). It aims to see if it improves breathing and is safe to use. Patients might continue their usual treatments.
Idiopathic Pulmonary FibrosisProgressive Fibrosing Interstitial Lung DiseaseSouth Korea - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
Relapsed and/or Refractory Multiple Myeloma (RRMM)South Korea - Active not recruitingPHASE1, PHASE2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.
Solid TumorsMetastatic MelanomaNon-small Cell Lung CancerEsophageal Squamous Cell CarcinomaSouth Korea - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaSouth Korea - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsSouth Korea - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerSouth Korea - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
Lymphoma, Non-HodgkinSouth Korea - Active not recruitingPHASE2
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study looks at a new drug, AZD9833, for post-menopausal women with advanced breast cancer that's hormone-sensitive (ER-positive) and HER2-negative. It compares AZD9833, taken by mouth, with an existing injected drug, Fulvestrant, to see which is safer and more effective.
Advanced ER-Positive HER2-Negative Breast CancerSouth Korea